Pay in 4 interest-free payments of $6.12 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Ask your clinician to send the prescription to LillyDirect
Pfizer discontinued danuglipron development due to significant tolerability issues, primarily gastrointestinal side effects such as nausea, vomiting, and diarrhoea that led to high discontinuation rates
They may include: They may include: Nausea Vomiting Diarrhea Vomiting Diarrhea Constipation Abdominal pain Decreased appetite Abdominal pain Decreased appetite Indigestion Redness at injection site Redness at injection site Most symptoms improve over time
Its unique dual mechanism enhances incretin effects, offering superior outcomes compared to traditional GLP-1RAs in recent trials, though its gastrointestinal tolerability profile warrants further scrutiny
The first theory hinges on how the drug works
US$ 29.67
US$ 29.00
US$ 29.76
US$ 25.83
